Celltrion applies sales approval of Herzuma to enter Japanese market
Celltrion announced it applied sales approval of Herzuma(CT-P6, generic name: trastuzumab), a self-developed anticancer antibody biosimilar, at the Japanese Ministry of Health, Labour and Welfare on the 11th to enter the Japanese market.
Herzuma, an anticancer antibody biosimilar used to treat b...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.